Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Dose-Escalation and Expansion Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, Immunogenicity, and Preliminary Efficacy of SGT003 in Patients With Advanced Solid Tumors

NCT07811037 is registered in ClinicalTrials.gov with Beijing Sungen Biomedical Technology Co., Ltd as lead sponsor.

NCT NCT07811037
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07811037 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Dose-Escalation and Expansion Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, Immunogenicity, and Preliminary Efficacy of SGT003 in Patients With Advanced Solid Tumors
Lead sponsor
Beijing Sungen Biomedical Technology Co., Ltd
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 17, 2026
Completion date
June 30, 2029
Enrollment
332 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor